Roivant Sciences Ltd., Director, 10% Owner at Immunovant, Inc. (IMVT), bought 16,845,010 shares at $20.00 ($336.9M) on 2025-01-13, disclosed to the SEC on 2025-01-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| IMVT | BUY | 2022-10-07 | $2.5M | — | Filing → |
| IMVT | BUY | 2020-09-04 | $12.5M | — | Filing → |
| IMVT | BUY | 2020-04-17 | $30.0M | — | Filing → |